Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$82.19
-1.9%
$82.13
$60.39
$85.89
$37.74B1.1332,263 shs27,116 shs
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
$20.00
-1.7%
$16.99
$11.14
$20.34
N/A0.33100 shs105 shs
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
$0.71
$0.60
$0.34
$0.77
$13.37B0.62,176 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
-1.90%-1.11%+1.18%+6.19%+20.25%
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
0.00%+0.25%+11.11%+33.51%+73.61%
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
0.00%+4.29%+1.01%+52.14%+92.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
N/AN/AN/AN/AN/AN/AN/AN/A
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
N/AN/AN/AN/AN/AN/AN/AN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
3.67
Strong BuyN/AN/A
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
0.00
N/AN/AN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$6.65B5.57$4.83 per share17.03$12.16 per share6.76
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
$53.73BN/A$4.37 per share4.58$42.43 per shareN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$1.36B$3.1326.2624.613.0220.72%27.81%11.74%7/30/2025 (Estimated)
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
$9.47BN/A0.00N/AN/AN/AN/AN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/AN/A0.00N/AN/AN/AN/A8/11/2025 (Estimated)

Latest SBMFF, CHCJY, and AMADY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025N/A
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$0.96N/AN/AN/A$1.88 billionN/A
5/8/2025Q1 2025
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$0.91$0.84-$0.07$0.83$1.71 billion$1.84 billion
4/29/2025Q1 2025
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
N/A$0.99N/A$0.99N/A$7.10 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$1.551.89%N/A49.52%N/A
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
$0.723.60%N/AN/AN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/AN/AN/A

Latest SBMFF, CHCJY, and AMADY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2025
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
$0.36184.26%6/26/20256/27/20259/2/2025
7/1/2025
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
$0.76451.34%7/3/20257/4/20257/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
0.56
1.19
1.19
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
N/AN/AN/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
N/A
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
N/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/A

Insider Ownership

CompanyInsider Ownership
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
N/A
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
N/A
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amadeus IT Group SA Unsponsored ADR stock logo
AMADY
Amadeus IT Group
20,643450.50 millionN/ANot Optionable
China CITIC Bank Corporation Limited stock logo
CHCJY
China CITIC Bank
66,891N/AN/ANot Optionable
Sino Biopharmaceutical stock logo
SBMFF
Sino Biopharmaceutical
25,80618.79 billionN/ANot Optionable

Recent News About These Companies

Sino Biopharmaceutical Ltd (1177) - Investing.com UK
SBMFF Sino Biopharmaceutical Limited
U.S. FDA Approves China-Produced Cancer Drug

Media Sentiment Over Time

Amadeus IT Group stock logo

Amadeus IT Group OTCMKTS:AMADY

$82.19 -1.59 (-1.90%)
As of 07/15/2025 03:54 PM Eastern

Amadeus IT Group, S.A., together with its subsidiaries, operates as a transaction processor for the travel and tourism industry worldwide. The company operates through three segments: Air Distribution, Air IT Solutions, and Hospitality & Other Solutions. The company acts as an international network providing real-time search, pricing, booking, and ticketing services, and other processing solutions through Amadeus GDS, Altéa PSS, and New Skies platforms. It also offers travel providers a portfolio of technology solutions, which automate certain mission-critical business processes, such as reservations, inventory management, and departure control. In addition, the company is involved in the provision of software development and definition, software distribution, regional support, data processing, intermediation, computer consulting, installation of industrial machinery and equipment, consultancy and technology development services for payments, and information technology services; financial activities; and e-commerce business. It serves providers of travel products and services, such as airlines, airports, hotels, tour operators, insurance companies, land and sea transport companies, travel sellers and brokers, and travel buyers. The company was formerly known as Amadeus IT Holding, S.A. and changed its name to Amadeus IT Group, S.A. in August 2016. Amadeus IT Group, S.A. was founded in 1987 and is headquartered in Madrid, Spain.

China CITIC Bank stock logo

China CITIC Bank OTCMKTS:CHCJY

$20.00 -0.34 (-1.67%)
As of 07/14/2025 10:45 AM Eastern

China CITIC Bank Corporation Limited provides various banking products and services in the People's Republic of China and internationally. The company operates in segments, such as Corporate Banking, Retail Banking, and Financial Market business. It accepts deposits; offers corporate and personal loans; and provides securities agency, remittance and settlement, and guarantee services, as well as investment banking and international services. The company also engages in the capital markets operations and inter-bank operations, including inter-bank money market transactions, repurchase transactions, investments, and trading in debt instruments; and derivatives and forex trading. In addition, it offers asset management, finance leasing, wealth management, ageing finance, private banking, credit card, payroll, and other non-banking financial services. The company serves corporations, government agencies, and non-financial institutions; and individual customers and micro and small enterprises. The company operates tier-one branches, tier-two branches, and sub-branches; self-service banks; and self-service terminals, as well as smart teller machines. The company was founded in 1987 and is headquartered in Beijing, the People's Republic of China. China CITIC Bank Corporation Limited operates as a subsidiary of CITIC Financial Holdings Co., Ltd.

Sino Biopharmaceutical stock logo

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.71 0.00 (0.00%)
As of 07/14/2025

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.